Cyclic Ketoximes as Estrogen Receptor β Selective Agonists

Area of Science:

• Medicinal Chemistry
• Molecular Pharmacology
• Oncology

Background:

• Estrogen receptor beta (ERβ)-selective agonists are a promising cancer therapy strategy.
• High homology between ERα and ERβ presents a significant challenge in developing selective agonists.

Purpose of the Study:

• To structurally evolve salicylketoxime-based molecules for enhanced ERβ selectivity.
• To identify novel ERβ-selective agonists with potential therapeutic applications.

Main Methods:

• Synthesis of novel five-membered cyclic ketoximes.
• In vitro binding assays to determine affinity and selectivity for ERα and ERβ.
• Cell-free coactivator recruitment assays to assess agonist activity.
• Molecular modeling studies to rationalize binding interactions.

Main Results:

• Two newly synthesized cyclic ketoximes exhibited nanomolar binding affinities for ERβ.
• These compounds demonstrated significant selectivity for ERβ over ERα.
• Coactivator recruitment assays confirmed their efficacy as ERβ agonists.
• Molecular modeling provided insights into the basis of their potency and selectivity.

Conclusions:

• The developed cyclic ketoximes represent a promising class of ERβ-selective agonists.
• These compounds hold potential for targeted cancer therapies by selectively modulating ERβ.
• Further investigation into their therapeutic efficacy and safety is warranted.